Stage I-III Breast Cancer Clinical Trial
Official title:
Circulating Tumor DNA Monitoring in Breast Cancer Undergoing Neoadjuvant Therapy
In the prospective, open, observational study, we aim to evaluate whether circulating tumor DNA (ctDNA) can be the marker of the response to neoadjuvant therapy in stage I-III breast cancer.
n/a